CLINICAL TRIALS

Travere Therapeutics is committed to research and development of new therapies for rare diseases.

We are involved in numerous clinical trials for our pipeline product candidates.

WE ARE CURRENTLY ENROLLING PATIENTS IN THE FOLLOWING CLINICAL STUDIES:

DUPLEX Study
Investigational therapy: Sparsentan
Therapeutic area: FSGS
Study type: Phase 3
Learn more: fsgsduplex.com | NCT03493685

PROTECT Study
Investigational therapy: Sparsentan
Therapeutic area: IgAN
Study type: Phase 3
Learn more: iganprotect.com | NCT03762850

RESTORE Study
Investigational therapy: Chenodeoxycholic acid
Therapeutic area: CTX
Study type: Phase 3
Learn more: CTXrestore.com | NCT02638220

CTX Prevalence Study
Therapeutic area: CTX among patients with early-onset idiopathic bilateral cataracts
Study type: Observational
Learn more: NCT02638220

TVT-058 (formerly OT-58)
Therapeutic area: HCU
Study type: Phase 1/2
Learn more: NCT03406611

Natural History Study of Homocystinuria Caused by Cystathionine Beta-synthase Deficiency
Therapeutic area: HCU
Study type: Observational
Learn more: NCT02998710

REPLACE Registry
Investigational therapy: Cholic acid
Therapeutic area: BASD; PBD-ZSD with liver involvement
Study type: Observational
Learn more: NCT03115086

ACTIVE CLINICAL STUDIES WITH COMPLETED ENROLLMENT:

DUET Study
Investigational Therapy: Sparsentan
Therapeutic area: FSGS
Study type: Phase 2
Learn more: NCT01613118

MA-304

© 2021 Travere Therapeutics, Inc. All rights reserved. For US audiences. Chenodal®, Cholbam® and Total Care HUB® are registered trademarks of Travere Therapeutics, Inc. Thiola® and Thiola EC® are registered trademarks of Mission Pharmacal Company.

Terms and Conditions | Privacy Policies | Cookie Settings